翰宇药业9月9日获融资买入1.13亿元，融资余额15.19亿元

Core Insights - On September 9, Hanyu Pharmaceutical experienced a decline of 1.68% with a trading volume of 1.406 billion yuan [1] - As of September 9, the total margin balance for Hanyu Pharmaceutical was 1.519 billion yuan, accounting for 7.16% of its circulating market value, indicating a high level of margin financing [1] - For the first half of 2025, Hanyu Pharmaceutical reported a revenue of 549 million yuan, representing a year-on-year growth of 114.86%, and a net profit of 145 million yuan, showing a significant increase of 1504.30% [2] Financing and Margin Data - On September 9, Hanyu Pharmaceutical had a margin buy-in of 113 million yuan and a margin repayment of 116 million yuan, resulting in a net margin buy of -2.89 million yuan [1] - The margin balance of 1.519 billion yuan is above the 90th percentile of the past year, indicating a high level of borrowing activity [1] - The short-selling data on September 9 showed no shares were sold or repaid, with a short-selling balance of 0, placing it in the 70th percentile of the past year [1] Shareholder and Dividend Information - As of June 30, the number of shareholders for Hanyu Pharmaceutical increased by 9.95% to 63,000, while the average circulating shares per person decreased by 3.98% to 11,841 shares [2] - Since its A-share listing, Hanyu Pharmaceutical has distributed a total of 417 million yuan in dividends, with no dividends paid in the last three years [2] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited held 7.6817 million shares, a decrease of 386,400 shares compared to the previous period [2]